

Edgar Filing: XOMA LTD /DE/ - Form 8-K

XOMA LTD /DE/  
Form 8-K  
October 10, 2003

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): October 10, 2003

XOMA LTD.

-----  
(Exact name of registrant as specified in its charter)

BERMUDA

-----  
(State or other jurisdiction of incorporation)

0-14710

52-2154066

-----  
(Commission File Number)

-----  
(IRS Employer Identification No.)

2910 Seventh Street, Berkeley, California

94710

-----  
(Address of principal executive offices)

-----  
(Zip code)

Registrant's telephone number, including area code

(510) 204-7200  
-----

-----  
(Former name or former address, if changed since last report)

Item 5. Other Events

As announced on October 10, 2003, XOMA Ltd. has discontinued development of MLN2201, a humanized monoclonal antibody being developed for conditions related

Edgar Filing: XOMA LTD /DE/ - Form 8-K

to inflammation of the heart and blood vessels. MLN2201 was one of two products of an ongoing development collaboration with Millennium Pharmaceuticals, Inc.

A copy of the press release is attached hereto as Exhibit 1 and is incorporated herein by reference.

Item 7. Exhibits

1. Press Release dated October 10, 2003.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: October 10, 2003

XOMA LTD.

By: /s/ Christopher J. Margolin

-----  
Christopher J. Margolin  
Vice President, General  
Counsel and Secretary

EXHIBIT INDEX

| Number | Description |
|--------|-------------|
| -----  | -----       |

1. Press Release dated October 10, 2003.